Jeff Hansen
| This email address is being protected from spambots. You need JavaScript enabled to view it.Research Editor
jeffhans@uab.edu | (205) 209-2355Communicates UAB research discoveries and initiatives from across the university for a variety of audiences.
Specific beats:
- Alabama Drug Discovery Alliance
- Biochemistry and Molecular Genetics
- Biomatrix Engineering and Regenerative Medicine
- Cell biology
- Center for Biophysical Sciences and Engineering
- CCTS
- Center for Metabolic Bone Disease
- Microbiology
- Neurobiology
- Comprehensive Neuroscience Center
- Pathology, research shared with MS2
- Pharmacology and Toxicology
- Physiology and Biophysics
- UAB Research Foundation/IIE
- Research Administration
Blacks face much greater rates of heart disease than do whites. A wider study is needed to further investigate this racial difference and identify potential therapeutic targets.
Anindya Dutta, M.D., Ph.D., and colleagues now have detailed the first structure-function study of this long non-coding RNA.
UAB physicians are working on the next steps to begin compassionate or emergency use of the pig kidneys in living humans. Two major approvals will be required.
In response to a viral infection, intrinsic IL-2 production by effector CD8 T cells affects IL-2 signaling, leading to different fates for two subsets of those cells — the one producing IL-2 and the one not producing IL-2.
Death or severe brain bleeding in the first week after birth dropped from 27.4 percent to 15 percent after introduction of a bundle of evidence-based, potentially better practices for preterm infants. Median weight of the 820 infants studied was 1 pound, 10 ounces.
The human preclinical model at UAB provides important knowledge before a Phase I clinical trial can begin for living human recipients. Decades of work by researchers across the world preceded UAB’s first clinical-grade pig kidney xenotransplant.
A detailed mechanistic study unravels how the bacterial endotoxin LPS prevents or promotes allergic disease.
Disruption of Blimp1 in regulatory T cells remodels the tumor microenvironment and augments the response to immunotherapy.
Research in animal models shows better formation of the fistulas, which are a lifeline for kidney failure patients as the connection site to dialysis machines.
At UAB, the company IN8bio Inc. is running a Phase I clinical trial to treat glioblastoma multiforme, the most aggressive type of cancer that originates in the brain.